Neuraxis Inc (NRXS) News & EventsNRXSNeuraxis Inc

Neuraxis Files to Sell 1.92M Shares of Common Stock

Neuraxis files to sell 1.92M shares of common stock for holders

NeurAxis Reports Q4 Net Loss of $1.7M

Reports Q4 net loss ($1.7M), up 18% vs. ($1.4M) in 4Q24. CEO Brian Carrico commented: "We believe NeurAxis has entered a new phase of its growth trajectory. With the Category I CPT code now in effect with positive policy coverage for more than 100 million covered lives, the foundation for scalable adoption of IB-Stim is firmly in place, and the opportunity in front of us is significantly easier for the market to understand. Our highest priority remains expanding medical policy coverage across the payer landscape, as each additional coverage win meaningfully increases patient access and reduces friction for providers. In parallel, our internal prior-authorization team continues to expand, helping hospital partners streamline reimbursement and increase confidence in adopting IB-Stim. The early part of 2026 has been focused on deploying our commercial strategy, learning from real-world utilization, and identifying the key drivers that accelerate adoption. With those insights now in hand and the reimbursement framework established, we believe we are positioned at the beginning of a multi-year growth cycle, with our focus squarely on disciplined execution and scaling utilization nationwide."

NeurAxis Secures Category I CPT Code for PENFS

NeurAxis announced that the Category I CPT code for Percutaneous Electrical Nerve Field Stimulation, PENFS, is now in effect, completing a successful commercial milestone for the Company. The assignment of the Category I CPT code is one of the "most significant breakthroughs in efforts towards widespread adoption of IB-Stim," the company said. This establishes a permanent, nationally recognized coding and billing pathway for NeurAxis' PENFS therapy, reflecting broad clinical acceptance and meeting the American Medical Association's, AMA, criteria for widespread utilization, clinical efficacy, and established standards of care.